Simulated population data suggests that the lifetime risk of cervical cancer is lower for women who stop screening after a negative DNA test for oncogenic HPV.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
The company and the hospital will conduct a clinical study into the detection and prevention of the disease.
Oncgnostics will use MDxHealth's methylation-specific PCR in the GynTect test for cervical cancer, the fourth such test to use the technology.
Paired with Roche's HPV testing offerings, the deal will expand its cervical cancer testing capabilities.
The German-based company expects to file its test for FFPE within the next few months, and to start a clinical trial for its cytology test by mid-year.
Roche presents data from HPV Dx trial; Epigenomics launches Epi proLung BL Reflex Assay in Europe.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.